Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
NextCure ( (NXTC) ) has provided an update.
On June 20, 2025, NextCure held its 2025 Annual Meeting of Stockholders where several key decisions were made. The stockholders elected three Class III members to the Board of Directors for a three-year term, ratified Ernst & Young LLP as the independent registered public accounting firm for 2025, approved executive compensation, and decided to hold a say-on-pay vote annually. Additionally, they approved an amendment for a reverse stock split, rendering the proposal for adjournment moot.
The most recent analyst rating on (NXTC) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on NextCure stock, see the NXTC Stock Forecast page.
Spark’s Take on NXTC Stock
According to Spark, TipRanks’ AI Analyst, NXTC is a Underperform.
NextCure’s overall stock score reflects significant financial challenges, including a lack of revenue and ongoing cash burn typical of early-stage biotech firms. The technical analysis suggests a bearish trend with potential volatility, while valuation metrics are unfavorable due to negative earnings. Despite a positive corporate event related to clinical trials, the company must urgently address its financial sustainability through partnerships or additional funding to enhance its long-term prospects.
To see Spark’s full report on NXTC stock, click here.
More about NextCure
Average Trading Volume: 250,948
Technical Sentiment Signal: Sell
Current Market Cap: $13.18M
Learn more about NXTC stock on TipRanks’ Stock Analysis page.